

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Komorowski et al.) Group Art Unit: 1651
App. No. : 10/001,322)
Filed : October 31, 2001)
For : METHODS AND COMPOSITIONS)
FOR THE IMPROVEMENT OF)
INSULIN SENSITIVITY, REDUCTION)
OF HYPERGLYCEMIA, AND)
REDUCTION OF)
HYPERCHOLESTEROLEMIA WITH)
CHROMIUM COMPLEXES AND)
ALPHA LIPOIC ACID)
Examiner : Patten, P.A.)

#16
3/1/03
3/6/03
RECEIVED
FEB 24 2003
TECH CENTER 1600/2000

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113 or after the mailing date of a Notice of Allowance under § 1.311. This Statement is accompanied by the fee set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410. A certification under 37 C.F.R. § 1.97(e) is set forth below.

Appl. No. : 10/001,322
Filed : October 31, 2001

FEB 7 2003

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/1/03

By: Mallary K. de Merlier

Mallary K. de Merlier
Registration No. 51,609
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\MKD\MKD-3530.DOC\021303